http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 08:03:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/EU+approves+AbbVie%27s+Boey+for+short-duration+frown+line+treatment/26782129.html <p>The European Commission has approved Boey (trenibotulinumtoxinE), a botulinum neurotoxin serotype E developed by Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, for the temporary improvement of moderate to severe glabellar lines in adult patients across all 30 European Economic Area countries.</p><p>According to the company's press release, Boey is the first botulinum neurotoxin serotype E approved in Europe. In clinical studies, onset of effect was observed as early as eight hours after treatment, with effects lasting approximately two to three weeks before glabellar lines returned to baseline severity.</p><p>The approval is supported by data from two Phase 3 randomized, double-blind, placebo-controlled trials http://www.streetinsider.com/Corporate+News/EU+approves+AbbVie%27s+Boey+for+short-duration+frown+line+treatment/26782129.html Fri, 17 Jul 2026 08:03:26 -0400 ABBV http://www.streetinsider.com/FDA/EU+approves+AbbVie%27s+Boey+for+short-duration+frown+line+treatment/26782129.html <p>The European Commission has approved Boey (trenibotulinumtoxinE), a botulinum neurotoxin serotype E developed by Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, for the temporary improvement of moderate to severe glabellar lines in adult patients across all 30 European Economic Area countries.</p><p>According to the company's press release, Boey is the first botulinum neurotoxin serotype E approved in Europe. In clinical studies, onset of effect was observed as early as eight hours after treatment, with effects lasting approximately two to three weeks before glabellar lines returned to baseline severity.</p><p>The approval is supported by data from two Phase 3 randomized, double-blind, placebo-controlled trials http://www.streetinsider.com/FDA/EU+approves+AbbVie%27s+Boey+for+short-duration+frown+line+treatment/26782129.html Fri, 17 Jul 2026 08:03:26 -0400 ABBV http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/Press+Releases/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html <div class="xn-content"> <ul type="disc"><li><i>Boey^® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> that adult patients can try for the temporary improvement of glabellar lines¹</i></li><li><i>Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks</i></li><li><i>Boey^® offers a differentiated treatment option for many people who are curious about facial injectables²</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.il.norago" idsrc="xmltag.org" >NORTH CHICAGO, Ill.</location></span>, <span class="legendSpanClass"><chron>July 17, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org" >AbbVie</span> company (NYSE: ABBV), announced the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> has approved Boey^® (trenibotulinumtoxinE) in http://www.streetinsider.com/PRNewswire/Allergan+Aesthetics+receives+approval+for+Boey%C2%AE+%28trenibotulinumtoxinE%29%2C+for+use+in+Europe%3A+the+first+and+only+rapid-onset%2C+short-duration+neurotoxin+for+the+temporary+improvement+of+frown+lines+in+ad/26782073.html Fri, 17 Jul 2026 08:00:00 -0400 A.17150087 A.22300475 A.50202117 A.60012004 ABBV O.01304637 O.14731390 O.15903254 O.34929518 O.37382289 http://www.streetinsider.com/Analyst+PT+Change/Abbvie+%28ABBV%29+PT+Raised+to+%24260+at+Citi/26769874.html Citi analyst Geoff Meacham raised the price target on Abbvie (NYSE: ABBV) to $260.00 (from $230.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Abbvie+%28ABBV%29+PT+Raised+to+%24260+at+Citi/26769874.html Wed, 15 Jul 2026 05:02:15 -0400 ABBV http://www.streetinsider.com/Corporate+News/SkinMedica+launches+advisory+board+and+expands+R%26D+lab+in+Irvine/26765209.html <p>Allergan Aesthetics, a unit of AbbVie (NYSE: ABBV), announced several initiatives for its SkinMedica skincare brand, including a new advisory board, an expanded research facility, and retail locations at select medical practices.</p><p>SkinMedica launched a Regenerative Science Advisory Board composed of physicians, clinicians, and skin health experts. The board will engage through in-person meetings, virtual consultations, and content on SkinMedica-owned platforms, with a focus on scientific dialogue and clinical best practices.</p><p>The company also expanded its SkinMedica research and development lab in Irvine, Calif., to more than double its previous footprint. The facility supports pre-clinical research and imaging technologies aimed at studying http://www.streetinsider.com/Corporate+News/SkinMedica+launches+advisory+board+and+expands+R%26D+lab+in+Irvine/26765209.html Tue, 14 Jul 2026 08:05:55 -0400 ABBV http://www.streetinsider.com/Press+Releases/SkinMedica%C2%AE+Deepens+Commitment+to+Regenerative+Science+with+Continued+Investment+in+Research+and+Development/26765199.html <div class="xn-content"> <ul type="disc"><li><i><span value="ACORN:3194222114" idsrc="xmltag.org" >SkinMedica</span></i><i>^®</i><i> launches <span>Regenerative Science Advisory Board</span> to shape future innovation</i></li><li><i>Expands its state-of-the-art research and development (R&amp;D) facility to support the next generation of science-led innovation</i></li><li><i>Debuts flagship retail experiences designed to support practice and patients' needs </i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.irvine" idsrc="xmltag.org" >IRVINE, Calif.</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- Allergan Aesthetics, an <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> (NYSE: ABBV) company, is proud to announce <span value="ACORN:3194222114" idsrc="xmltag.org" >SkinMedica's</span> expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.</p> <p>"Stemming from its origins in wound-healing research, <span value="ACORN:3194222114" idsrc="xmltag.org" >SkinMedica</span> was founded on the principles http://www.streetinsider.com/Press+Releases/SkinMedica%C2%AE+Deepens+Commitment+to+Regenerative+Science+with+Continued+Investment+in+Research+and+Development/26765199.html Tue, 14 Jul 2026 08:05:00 -0400 A.31942221 ABBV O.14731390 O.57040878